Merck & Co. drops osteoporosis drug odanacatib
نویسندگان
چکیده
منابع مشابه
Odanacatib, a New Drug for the Treatment of Osteoporosis: Review of the Results in Postmenopausal Women
Osteoclasts are specialized cells that initiate the process of bone resorption, which has two phases, dissolution of the mineral component and degradation of the organic matrix, in which cathepsin K plays a key role. Cathepsin K inhibitors, which block the activity of cathepsin on bone resorption lacunae, may be a new therapeutic option in osteoporosis. Odanacatib is a nonpeptidic biaryl inhibi...
متن کاملPotential role of odanacatib in the treatment of osteoporosis
Cathepsin K is a key enzyme involved in the degradation of organic bone matrix by osteoclasts. Inhibition of bone resorption observed in human and animal models deficient for cathepsin K has identified this enzyme as a suitable target for intervention by small molecules with the potential to be used as therapeutic agents in the treatment of osteoporosis. Odanacatib (ODN) is a nonbasic selective...
متن کاملOdanacatib, a cathepsin K inhibitor for the treatment of osteoporosis and other skeletal disorders associated with excessive bone remodeling.
Odanacatib (MK-0822, MK-822) is an orally administered cathepsin K inhibitor being developed by Merck & Co Inc, under license from Celera Group, for the treatment of osteoporosis and bone metastases. Cathepsin K, a lysosomal cysteine protease that is expressed by osteoclasts during the process of bone resorption, acts as the major collagenase responsible for the degradation of the organic bone ...
متن کاملOdanacatib: a possible new therapeutic option for the treatment of osteoporosis
Throughout life, bone remodeling maintains the structure of bone tissue, leading to changes in bone density, shape and strength that allow it to adapt to biomechanical circumstances at any given time. This remodeling occurs both in cortical bone, which is responsible for load bearing, and in trabecular bone, which participates in the regulation of mineral homeostasis and bone strength. Bone rem...
متن کاملOdanacatib: a review of its potential in the management of osteoporosis in postmenopausal women.
Odanacatib is a cathepsin K inhibitor developed for the treatment of postmenopausal osteoporosis. It is a bone resorption inhibitor, but which preserves bone formation to some extent. It can be administered once a week, in tablets also containing vitamin D. In a large clinical development program, it has been shown that odanacatib reduces bone resorption, with a reduction of about 60-70% in bio...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Nature Reviews Drug Discovery
سال: 2016
ISSN: 1474-1776,1474-1784
DOI: 10.1038/nrd.2016.207